WUXI APPTEC - Overseas Regulatory Announcement - Business Update

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We are not responsible for any losses caused by reliance on such content.

WUXI APPTEC CO., LTD.* Wuxi WuXi AppTec New Drug Development Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 2359)

Overseas Regulatory Announcements

This overseas regulatory announcement is made by the Company in accordance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

Section 13.10B is made.

The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only.

By order of the board of directors Wuxi WuXi AppTec New Drug Development Co., Ltd. Chairman

Dr. Li Ge

Hong Kong, August 3, 2026

As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; Non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong.

*For identification only

Summary of the 2026 Semi-Annual Report of Wuxi WuXi AppTec New Drug Development Co., Ltd.

Company code: 603259 Company abbreviation: WuXi AppTec

Wuxi WuXi AppTec New Drug Development Co., Ltd.

2026 Interim Report Summary

Summary of the 2026 Semi-Annual Report of Wuxi WuXi AppTec New Drug Development Co., Ltd.

Section 1 Important Tips

1.1 This summary of the semi-annual report is derived from the full text of the semi-annual report. It provides a comprehensive understanding of the company’s operating results, financial status and future development.

For development planning, investors should go to the website http://www.sse.com.cn to carefully read the full text of the semi-annual report.

1.2 The company’s board of directors, directors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report.

We shall bear individual and joint legal liability for false records, misleading statements or major omissions.

1.3 All directors of the company shall attend the board meeting.

1.4 This semi-annual report has not been audited.

1.5 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors

The company plans to distribute a cash dividend of RMB 5.1,000 (tax included) to all shareholders for every 10 shares. At present, the company’s special securities account for A-share repurchase 9,701,231 shares have been repurchased, and 20,148,900 H-share treasury shares have been repurchased. The aforementioned total of 29,850,131 shares will not participate in dividends. At present, the company's total share capital is 2,983,757,155 shares, after deducting the repurchased shares and H-share treasury shares in the company's special securities account for A-share repurchase.

Calculated based on 2,953,907,024 shares of capital stock, a total cash dividend of RMB 1,506,492,582.24 (including tax) was distributed. in implementation Before the equity registration date for equity distribution, the company enjoys the right to profit distribution (that is, deducting the repurchased shares and H shares in the company’s special securities account for A share repurchase). If there is a change in the total share capital (treasury shares), distribution will be carried out based on the principle that the distribution amount per share remains unchanged, and the total distribution amount will be adjusted accordingly.

Summary of the 2026 Semi-Annual Report of Wuxi WuXi AppTec New Drug Development Co., Ltd.

Section 2 Basic Information of the Company

2.1 Company Profile Company Stock Profile Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change

A shares Shanghai Stock Exchange WuXi AppTec 603259 Not applicable H shares Stock Exchange WuXi AppTec 02359 Not applicable

Contact and Contact Information Secretary of the Board Securities Affairs Representative Name Han Min Fei Xiaqi, Wang Li Phone +86(21)2066-3091 +86(21)2066-3091 Waigaoqiao Bonded Area, Pudong New Area, Shanghai, China China Waigaoqiao Bonded Area, Pudong New Area, Shanghai, China Office address No. 288, Fute Middle Road, District No. 288, Fute Middle Road, Tax District Email [email protected] [email protected]

2.2 Main financial data Unit: Yuan Currency: RMB

The end of this reporting period compared with the previous year End of this reporting period End of previous year Increase or decrease in degree (%) Total assets 116,262,551,499.28 103,120,968,579.11 12.74 Net assets attributable to shareholders of listed companies 83,333,717,174.75 79,712,290,246.44 4.54 This reporting period is the same as last year’s This reporting period the same period last year Period increase or decrease (%) Operating income 28,897,478,718.36 20,799,281,882.46 38.93 Total profit 13,517,559,065.27 9,907,416,557.97 36.44 Net profit attributable to shareholders of listed companies 11,080,173,661.42 8,560,882,627.56 29.43 Deductions attributable to shareholders of listed companies are not 10,572,177,317.83 5,582,126,598.19 89.39 Net profit from ordinary gains and losses Net cash flow generated from operating activities 9,699,142,388.08 7,430,981,531.70 30.52 Weighted average return on equity (%) 13.19 13.93 decreased by 0.74 percentage points Basic earnings per share (yuan/share) 3.80 3.01 26.25 Diluted earnings per share (yuan/share) 3.76 2.99 25.75 2.3 List of shareholdings of the top 10 shareholders Unit: Share Total number of shareholders (households) as of the end of the reporting period (Note 1) 261,426 Total number of preference shareholders whose voting rights were restored as of the end of the reporting period (households) 0 Shareholding status of the top 10 shareholders

Hold limited pledge, mark Shareholding ratio Shareholding Name of shareholder Nature of shareholder Conditions for sale or frozen shares (%) Quantity Number of shares Number of shares HKSCC NOMINEES LIMITED Overseas legal person 17.1071 510,434,758 0 Unknown 0 (Note 2) Hong Kong Securities Clearing Company Limited (Note 3) Overseas legal person 8.7663 261,564,313 0 None 0 G&CVILimited Overseas legal person 4.2667 127,309,054 0 None 0

Summary of the 2026 Semi-Annual Report of Wuxi WuXi AppTec New Drug Development Co., Ltd.

G&CIVHongKongLimited Overseas legal person 3.1214 93,135,472 0 None 0 Beijing Zhongmin Yinfu Investment Management Co., Ltd.

Company - Jiaxing Yuxiang Investment Partnership (with Others 2.5978 77,511,585 0 None 0 limited partnership) G&CVLimited Overseas legal person 2.1810 65,076,978 0 None 0 China Construction Bank Co., Ltd.- E Fund CSI 300 Medical and Health Transactions Others 1.3473 40,201,222 0 None 0

open-end index securities investment fund G&CVIILimited Overseas legal person 1.1293 33,696,017 0 None 0 SUMMER BLOOM Overseas legal person 1.0632 31,721,901 0 None 0 INVESTMENTS(I)PTE.LTD. Shanghai Houshen Investment Center (Limited Partnership) Others 1.0407 31,051,061 0 None 0 The top ten shareholders of the company are G&CVILimited and G&CIVHong KongLimited, G&CVLimited, G&CVIILimited, Explanation on the related relationships or concerted actions of the above shareholders Beijing Zhongmin Yinfu Investment Management Co., Ltd. - Jiaxing Yuxiang Investment Partnership (Limited Partnership), Shanghai Houshen Investment Center (Limited

partnership) acting in concert. Description of preference shareholders with restored voting rights and number of shares held Not applicable Note 1: As of the end of the reporting period, the total number of ordinary shareholders was 261,426, including 261,368 A-share shareholders and 58 H-share registered shareholders. Note 2: HKSCCNOMINEESLIMITED is Hong Kong Securities Clearing Company (Nominees) Limited, and its shares represent multiple held by customers.

Note 3: Hong Kong Securities Clearing Company Limited is the nominal holder of Shanghai-Hong Kong Stock Connect RMB ordinary shares.

2.4 Total number of preference shareholders and top 10 preference shareholders as of the end of the reporting period

□Applicable √Not applicable

2.5 Changes in controlling shareholders or actual controllers □Applicable √Not applicable

2.6 Status of bonds existing on the date of approval of the semi-annual report □Applicable √Not applicable

Summary of the 2026 Semi-Annual Report of Wuxi WuXi AppTec New Drug Development Co., Ltd.

Section 3 Important Matters

The company shall, in accordance with the principle of materiality, explain the significant changes in the company's operating conditions during the reporting period, as well as the impact on the company that occurred during the reporting period. Matters that have a significant impact on operating conditions and are expected to have a significant impact in the future □Applicable √Not applicable